generation recombinant adenovirus containing a utrophin minigene. Up to 95% of the fibres continued expressing the minigene 30 days after injection. Expression of utrophin caused a marked reduction from 80% centrally nucleated fibres (CNFs) in the uninjected dko TA to 12% in the injected dko TA. Within the region of the TA expressing the utrophin minigene, a significant decrease in the prevelance of necrosis was noted. These results demonstrate that the utrophin minigene delivered using an adenoviral vector is able to afford protection to the dystrophin/utrophin-deficient muscle of the dko mouse. Gene Therapy (2000) 7, 201-204. addressed in the form of gutted adenoviruses, viable viruses that only contain the inverted terminal repeats and a packaging signal of the adenoviral genome and consequently do not produce any viral proteins. 7 However, delivery of dystrophin still could pose a problem, possibly requiring the use of long-term immunosuppressive regimens. 8 Utrophin is a ubiquitously expressed protein similar in amino acid sequence to dystrophin. 9, 10 In adult skeletal muscle, however, it is restricted to the neuromuscular and myotendinous junctions and is thought to play a role in the maintenance of junctional folds. 11 Studies in vitro have shown that utrophin is able to bind both to actin and to the DPC. 12 Furthermore, it is known that in normal fetal muscle, utrophin is localised to the extrajunctional sarcolemma before being replaced by increasing levels of dystrophin during development. 13 In regenerating muscle fibres, utrophin is also localised at the extrajunctional sarcolemma. Thus it is proposed that utrophin could offer a replacement role for dystrophin. 10 We have shown that up-regulation of utrophin in transgenic mdx mice results in its localisation to the sarcolemma and correction of the dystrophic phenotype. 14, 15 As utrophin is already present in DMD patients, there will be no immune problems with the delivery of a utrophin gene. Using a first generation adenovirus, we decided to explore the delivery of utrophin to dystrophic mouse muscle. However, due to the limited 8 kb insert capacity of this adenovirus, a truncated utrophin minigene was employed. This has been constructed through sequence comparison with a truncated dystrophin minigene that lacks a proportion of the rod domain, as ascertained from a mildly affected Becker muscular dystrophy patient. 14 Previous experiments for the delivery of a utrophin containing adenovirus to dystrophic muscle have utilised the mdx mouse. 16 Although the mdx mouse does show an underlying dystrophic pathology and hence has proved a valuable model for DMD, it does not show the severe and progressive muscle wasting observed in a DMD patient (other than in the diaphragm), and has a normal life span. Furthermore, the mdx mouse shows significant levels of utrophin localised to the sarcolemma of regenerating fibres thus leading to difficulty when trying to assess the delivery of a therapeutic utrophin gene. We therefore used the severely affected dystrophin/ utrophin-deficient double knockout (dko) mice. 17, 18 In contrast to mdx mice, dko mice show many more clinical signs of DMD, which include a marked weight loss following weaning with an onset of joint contractures and kyphosis leading to premature death by 20 weeks of age. These mice show progressive muscular dystrophy and therefore provide an excellent model to observe an improvement in the clinical features of DMD.
We have used an E1 + E3-deleted adenovirus vector containing the truncated utrophin minigene under the control of a murine cytomegalovirus promoter/enhancer. This was injected into the tibialis anterior (TA) of 5-dayold dko mice at a titre of 1.7 × 10 11 p.f.u. (5 l). The contralateral TA muscle was left uninjected to serve as a negative control for the immunostaining and also to observe the extent of damage caused to the muscle during the injection procedure. The mice were killed after 30 days following which the TA muscles were removed for immunostaining to detect the presence of utrophin and components of the DPC, and staining with haemotoxylin and eosin to observe muscle pathology.
Staining with antibodies to the C-terminal region of utrophin 14 revealed that 95% of the fibres at the site of the injection were now expressing the recombinant utrophin at the muscle fibre surface. Staining was not restricted to the neuromuscular junctions but was observed to be uniformly distributed along the sarcolemma ( Figure  1) . In many fibres, expression of utrophin was so high that cytoplasmic staining was also observed. Unlike with mdx mice, there was no spontaneously up-regulated utrophin expression, which is difficult to distinguish from the delivered protein. Sections from the uninjected contralateral TA used as a control did not stain with the utrophin antibodies ( Figure 1 ).
In common with DMD patients, lack of dystrophin in both mdx and dko mice results in a reduction of the DPC at the sarcolemma. In order to show that the delivered utrophin had the ability to restore the DPC, antibodies against ␣-dystrobrevin, ␣-sarcoglycan and ␤-dystroglycan were used (Figure 1) . In all cases, the presence of sarcolemma-bound utrophin coincided with a restoration of members of the DPC. No restoration of the DPC was observed in the contralateral control muscle (Figure 1) .
The delivered utrophin affords a protective function to the muscle fibre by preventing necrosis and regeneration thus remains low (Figure 2 ). In the dko mice a major period of necrosis occurs at around 20 days of age following which the fibres retain centralised nuclei but degeneration occurs at a much slower rate. It is interesting to note that this period of necrosis occurs about a week later in mdx mice suggesting that the low levels of sarcolemmal-bound endogenous utrophin may be beneficial. There is a significant prevention in the formation of CNFs from an average of 80% in the TA of the uninjected leg to an average of 12% in the injected TA (Figure 3) . Also, the fibres are more uniform in their size, again indicating a reversion to a normal phenotype. The level of macrophage infiltration is significantly lower in the injected TA, with the levels present being accounted either by the actual injection technique or through an immune reaction against adenoviral proteins (Figure 2 ). The morphology of the muscle as determined by analysis of H&E sections from mice that were injected before necrosis had commenced, showed a similar level of macrophage infilGene Therapy tration in the injected leg with none being observed in the control leg (data not shown).
Figure 2 Haemotoxylin and eosin stained sections to show a reduction in the numbers of centrally nucleated fibres (CNFs) when dko dystrophic muscle is injected with a utrophin containing adenovirus. Macrophage infiltration (MP) and necrosis is markedly decreased and the majority of fibres contain peripherally located nuclei (PNF).
Thus we have demonstrated successful delivery of a utrophin minigene to dystrophic limb muscle of the dystrophin/utrophin dko mouse. Using an adenovirus vector it was possible to transduce up to 95% of the muscle fibres around the site of the injection. A significant decrease in the number of CNFs from 80% in the uninjected control TA to just 12% in the injected TA and a marked decrease in the level of macrophage infiltration shows that the delivered utrophin is able to protect the muscle from necrosis.
It has been suggested that functional correction of muscle groups would require a minimum of 20% of the fibres to be expressing dystrophin. 19 Assuming that utrophin levels would need to be similar, infection of 95% of the fibres would provide for a normalised phenotype. Observing sections at the other end of the muscle from where the injection was carried out showed levels of between 50 and 60% utrophin expression (data not shown). This indicates that the adenovirus is able to spread throughout the small murine TA muscle and maintain a level of infectivity that would still be therapeutic. However, it must be considered that the adenovirus would not show much impressive spread throughout larger muscles. Analysis of the soleus muscle of an injected leg shows that the virus is unable to spread from one muscle to the next, an observation that has been alluded to previously using ␤-galactosidase expressing adenoviruses. 20 This work demonstrates that it is possible to deliver a therapeutic utrophin gene to dystrophic muscle of the dko mouse and afford substantial protection against muscle necrosis and a dystrophic phenotype.
